ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Vinorelbine as third line therapy in patients with advanced non-small cell lung cancer: Department of Clinical Oncology - Ain Shams University experience
Research in Oncology
◽
10.21608/resoncol.2014.465
◽
2014
◽
Vol 10
(Issue 3-4)
◽
pp. 86-90
Author(s):
Nesreen Mosalam
◽
Engi El Kholy
◽
Mai Ezz El Din
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Clinical Oncology
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
◽
University Experience
Download Full-text
Related Documents
Cited By
References
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
◽
10.1097/jto.0b013e3182614835
◽
2012
◽
Vol 7
(10)
◽
pp. 1594-1601
◽
Cited By ~ 20
Author(s):
Vassiliki A. Papadimitrakopoulou
◽
Jean-Charles Soria
◽
Annette Jappe
◽
Valentine Jehl
◽
Judith Klimovsky
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2016.11.1732
◽
2017
◽
Vol 12
(1)
◽
pp. S1229-S1230
Author(s):
Nikhil Pande
◽
Amit Joshi
◽
Vanita Noronha
◽
Vijay Patil
◽
Anuradha Chougule
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
Lung Cancer
◽
10.1016/j.lungcan.2009.07.008
◽
2010
◽
Vol 68
(3)
◽
pp. 433-437
◽
Cited By ~ 12
Author(s):
Mario Scartozzi
◽
Paola Mazzanti
◽
Riccardo Giampieri
◽
Rossana Berardi
◽
Eva Galizia
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Predictive Factors
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
◽
Nsclc Patients
Download Full-text
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
Annals of Oncology
◽
10.1093/annonc/mdq682
◽
2011
◽
Vol 22
(8)
◽
pp. 1805-1811
◽
Cited By ~ 25
Author(s):
A.M. Horgan
◽
P.A. Bradbury
◽
E. Amir
◽
R. Ng
◽
J.Y. Douillard
◽
...
Keyword(s):
Lung Cancer
◽
Economic Analysis
◽
Small Cell Lung Cancer
◽
Randomized Trial
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients
Medical Oncology
◽
10.1007/s12032-010-9753-3
◽
2010
◽
Vol 28
(S1)
◽
pp. 605-612
◽
Cited By ~ 7
Author(s):
Zhengbo Song
◽
Yongfeng Yu
◽
Zhiwei Chen
◽
Shun Lu
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cancer Patients
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Lung Cancer Patients
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine
Journal of Clinical Oncology
◽
10.1200/jco.2014.57.5621
◽
2015
◽
Vol 33
(5)
◽
pp. 524-524
◽
Cited By ~ 6
Author(s):
Bivas Biswas
Keyword(s):
Lung Cancer
◽
Personalized Medicine
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
◽
10.1097/jto.0b013e318282709c
◽
2013
◽
Vol 8
(3)
◽
pp. 369-372
◽
Cited By ~ 29
Author(s):
Suresh S. Ramalingam
◽
Taofeek K. Owonikoko
◽
Madhusmita Behera
◽
Janakiraman Subramanian
◽
Nabil F. Saba
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Phase Ii
◽
Cell Lung Cancer
◽
Phase Ii Study
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
Investigational New Drugs
◽
10.1007/s10637-013-9980-5
◽
2013
◽
Vol 32
(1)
◽
pp. 195-199
◽
Cited By ~ 23
Author(s):
Tien Hoang
◽
Toby C. Campbell
◽
Chong Zhang
◽
KyungMann Kim
◽
Jill M. Kolesar
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Phase Ii
◽
Cell Lung Cancer
◽
Phase Ii Study
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study
The Journal of Medical Investigation
◽
10.2152/jmi.55.260
◽
2008
◽
Vol 55
(3,4)
◽
pp. 260-266
Author(s):
Naoki Nishimura
◽
Rika Sugiura
◽
Hirotaka Ueda
◽
Hiroshi Ono
◽
Hidehito Horinouchi
◽
...
Keyword(s):
Lung Cancer
◽
Pilot Study
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Combination Chemotherapy
◽
Small Cell
◽
Small Cell Lung
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Annals of Oncology
◽
10.1016/j.annonc.2020.08.1629
◽
2020
◽
Vol 31
◽
pp. S850
Author(s):
E. Felip
◽
F.L. Lim
◽
M. Johnson
◽
M. O'Brien
◽
F. Barlesi
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase Ib
◽
Line Therapy
◽
Third Line Therapy
◽
Third Line
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close